Skip to content
DE

Akkermansia sp004167065: What a stool test can show

Clinical review pending

How Akkermansia sp004167065 is measured in the microbiome, which functions are under discussion and why a single value does not provide a diagnosis.

Akkermansia sp004167065: A single species within the genus

A test for Akkermansia sp004167065 looks at what share of a stool sample belongs to this genetically defined bacterial species. The odd string of digits is not the name of a disease. It comes from a genome-based taxonomy that can tell apart closely related lineages within the genus Akkermansia. Depending on the product, labs use either 16S rRNA analysis or shotgun metagenomic sequencing. Not every method can separate this species from its relatives equally well.

Akkermansia lives close to the gut’s mucus layer and can use mucin as a food source. Breaking down mucin is part of the normal exchange between microbes and the intestinal lining; it is not automatically a sign of a damaged barrier. The process produces acetate and propionate, among other compounds. By trading metabolic products with other bacteria, organisms like this can become part of larger fermentation networks, which also include butyrate producers.

Research links members of the genus to metabolic traits and inflammatory processes. Much of that work, however, concerns Akkermansia muciniphila or the genus as a whole. The findings cannot simply be carried over to sp004167065. A stool value is also a snapshot, not a fixed and permanent trait of a person.

Why looking at the species level can add information

Diet, the mucus layer and the immune system all influence one another. That makes it biologically plausible to look at Akkermansia in the context of the rest of the gut community. A low share could be related to changed conditions in the mucosal environment. A high share in someone eating very little fiber could, in turn, point to heavier use of the body’s own mucus. None of these processes can be demonstrated from the test alone.

People often become interested in this kind of analysis after antibiotics, long stretches of restrictive eating or persistent digestive complaints. Changes in sleep, stress, weight or blood sugar can also be a reason to take a closer look. A profile like this can add to the information already available. An Akkermansia result does not automatically explain symptoms, and it does not replace testing for common, treatable causes.

In the long run, eating patterns, exercise and sleep matter for overall health. Whether changing those habits improves the measured share of sp004167065 specifically, and whether that brings any clinical benefit, is a separate question. So the goal should not be a supposedly perfect single number. What matters more are symptoms, medically meaningful tests and a diet that you can tolerate in everyday life.

What the Akkermansia sp004167065 number actually tells you

Most reports give the relative abundance: the share of assigned DNA relative to all microbial DNA. Some also give a percentile compared with a reference group. This is neither an absolute cell count nor a measure of current metabolic activity. A relative share can rise because other species decline, even when the absolute amount of Akkermansia has barely changed.

Healthy people differ considerably in their microbiome makeup. Diet, region, age and other individual factors shape the result. That is why there is no universally valid target value for this species. A range a provider labels “optimal” is a lab-specific classification, not proof of an intact gut barrier, adequate production of short-chain fatty acids or low inflammatory activity.

Likewise, a low or undetectable value does not necessarily mean something is missing. Possible explanations include technical detection limits, fluctuations over time or a different mix of functionally similar organisms. A high share has to be read in the context of the whole community, diet and symptoms. Neither a low nor a high value justifies targeted treatment on its own.

How the value fits into the bigger picture

When medically indicated, blood glucose, inflammatory markers, liver values or established stool markers can answer additional questions. These tests, however, measure different things. If several values change together, that does not automatically mean Akkermansia caused an improvement or a decline in health.

Several limitations deserve particular attention. A stool sample mainly reflects the contents of the gut, while Akkermansia often lives near the mucosa. Databases and analysis pipelines can assign the same sequence differently. DNA shows presence, not necessarily living or active organisms. Antibiotics, bowel prep before a colonoscopy, acute infections and improper sample transport can all shift the result. Without this information, a precise percentage looks more meaningful than it is clinically.

Frequently asked questions

What does the test for Akkermansia sp004167065 measure?

The specific value describes whether this species was detected and, usually, its relative abundance. A comprehensive microbiome profile may also cover other bacteria and, depending on the method, other microorganisms or functional genes. These extras are not automatically part of every Akkermansia test. The analysis describes composition and possible functional potential; it does not prove any disease.

How is the sample collected?

Usually you collect a small amount of stool at home using the tube or swab system supplied. Wash your hands before and after, do not touch the inner surfaces and avoid contamination. Follow the specific lab’s instructions exactly for labeling, sealing, storage and shipping. Different kits can use different preservative solutions and time windows.

What can the result say about my health?

It can offer clues about the makeup of a gut community whose members take part in mucus metabolism, fermentation and immune signaling pathways. Links to weight, glucose metabolism or gut-brain communication are research topics. They do not allow an individual prediction of mood, nutrient absorption or disease risk based on this single species. Medical history and clinical findings remain decisive.

How reliable is the measurement?

Sequencing can capture microbial DNA in fine detail. Its resolution, though, depends on sequencing depth, sample quality, the reference database and the bioinformatic analysis. Telling closely related species apart in particular depends on the method. And a technically reproducible result does not mean there is a validated medical recommendation for what to do with the value.

How often should you test?

There is no established general screening standard for annual measurements or for checks every three to six months during dietary changes. Repeat tests only make sense if you have first settled which specific question they will answer and whether the result would influence a meaningful decision. For comparisons, the lab, method and collection conditions should stay as similar as possible.

Can the populations change quickly?

Yes. Diet, antibiotics, travel, illness and changed routines can cause measurable shifts within a few days. More stable patterns often develop over weeks or months. A short-term rise after an intervention therefore proves neither a lasting effect nor a health benefit.

Does the test provide a diagnosis?

No. Even unusual abundances are not a diagnosis in their own right. In particular, they must not be equated with a proven gut barrier disorder. With persistent symptoms, a clinical workup matters more than optimizing a microbiome chart.

How can a result be used in practice?

A varied, plant-rich diet that suits you individually supplies a range of fibers and polyphenols. If you have symptoms, adjust fiber gradually. The measured value does not tell you a suitable dose of inulin, resistant starch or a probiotic. Specialized microbial products need their own assessment of product, strain, safety and efficacy. Drinking enough, exercise and good sleep can support general health goals, but they are not a guaranteed therapy for an Akkermansia value. If you have a medical condition or take medication, targeted changes should be agreed with a qualified professional.

Sources

  • Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences of the United States of America, 110(22), 9066-9071. https://doi.org/10.1073/pnas.1219451110 PubMed

  • Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A (2021). Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Scientific Reports, 11, 3030. https://doi.org/10.1038/s41598-021-82726-y PubMed

  • Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041 PubMed

  • Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. The New England Journal of Medicine, 375(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266 PubMed

  • Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O’Toole PW, Raes J, Hold G, Putignani L, Gasbarrini A, Segata N, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X PubMed